drugset / Trial / NCT02230384
Novel Smoking Cessation Drug for Schizophrenia
Phase 2
Completed
62 enrolled
K.N. Roy Chengappa
National Institutes of Health (NIH) · collabUniversity of Pittsburgh · collabVirginia Commonwealth University · collab
RandomizedCrossoverQuadruple-blindBasic science
Summary
The investigators will evaluate effects of a novel drug that improves nicotinergic receptor function vs. placebo on short-term smoking abstinence in smokers with schizophrenia who have a high interest in quitting. The investigators predict that the novel drug will increase days of abstinence, compared with placebo, identifying potential evidence of efficacy for smoking cessation in smokers with schizophrenia. The investigators will also assess if this new drug decreases nicotine withdrawal, craving, and cognitive impairment during early abstinence, as well as evaluate adverse effects.
Timeline
- Start
- 2014-09
- Primary completion
- 2016-12-16
- Completion
- 2017-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Active JNJ Drug | Unknown | 100 mg | — |
Indications
No indication recorded.